Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Cash & Equivalents for 11 consecutive years, with $62.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.43% year-over-year to $62.1 million; the TTM figure through Mar 2026 stood at $62.1 million (down 41.43% YoY), while the FY2025 annual figure was $54.3 million, down 39.08% from the prior year.
• Cash & Equivalents improved to $62.1 million in Q1 2026 per RYTM's latest filing, from $54.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $416.1 million in Q3 2025 and bottomed at $48.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $116.8 million across 5 years, with a median of $106.1 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 64.99% — and 2025, when it jumped 767.18%.
• Rhythm Pharmaceuticals' Cash & Equivalents stood at $128.0 million in 2022, then plunged by 52.81% to $60.4 million in 2023, then jumped by 47.56% to $89.1 million in 2024, then plunged by 39.08% to $54.3 million in 2025, then increased by 14.43% to $62.1 million in 2026.
• Business Quant data shows RYTM's Cash & Equivalents at $62.1 million in Q1 2026, $54.3 million in Q4 2025, and $416.1 million in Q3 2025.